Navigation Links
Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
Date:9/2/2012

VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.  As previously announced, EP-101 demonstrated a rapid onset, dose-related, statistically significant improvement in lung function compared to placebo.  EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an investigational eFlow® nebulizer (PARI Pharma GmbH). 

The GOLDEN-1 study (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer), was a Phase 2b, randomized, placebo-controlled, double-blind, seven-arm, four-period cross-over, incomplete block design, dose-ranging study with seven days of once-daily dosing to assess the pharmacokinetics, safety and efficacy of EP-101 in 140 patients with moderate-to-severe COPD.  All four doses (25mcg, 50 mcg, 100 mcg and 200 mcg) of EP-101 administered as once daily for seven days using the investigational eFlow provided a rapid onset of action (five minutes), short treatment time (two minutes), and a robust magnitude of bronchodilation compared to placebo.  The bronchodilatory improvements on day seven as assessed by 24-hour forced expiratory volume in one second (FEV1)  and the FEV1 AUC (0-12 hours and 12-24 hours) were dose-dependent, statistically significant (p<0.001) at all doses compared to placebo, and clinically meaningful at several doses compared to placebo.  In addition, the improvements in lung function with EP-101 doses were comparable to those of once-daily tiotropium dry powder inhaler and three- times daily nebulized ipratropium administered via jet nebulizer.
'/>"/>

SOURCE Elevation Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
2. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
3. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
4. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
5. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
6. Global RFID in Healthcare and Pharmaceuticals Industry
7. Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
8. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
10. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. Isis Pharmaceuticals to receive $1.4 million from Alnylam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 CEFALY ... electrical nerve stimulation device specifically authorized for use prior ... data from a new PET trial showing that the ... in the brain in migraine patients, namely the orbitofrontal ... Tomography (PET) scan, which is an imaging test of the brain, used ...
(Date:6/1/2015)... SETAUKET, N.Y. , June 1, 2015 /PRNewswire/ ... (NASDAQ: HRTX ) today announced positive, top-line ... study.  MAGIC evaluated the efficacy and safety of ... candidate SUSTOL ® (granisetron injection, extended release) ... intravenous (IV) neurokinin-1 (NK 1 ) receptor antagonist ...
(Date:6/1/2015)... 2015   OTC Markets Group Inc. ... financial marketplaces for 10,000 U.S. and global securities, ... Diego -based biopharmaceutical company, on its NASDAQ ... public venture market for entrepreneurial and development stage ... "We,re happy to congratulate OncoSec ...
Breaking Medicine Technology:New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... , , INDIANAPOLIS, Dec. 18 ... today announced that Derica Rice, senior vice president and chief ... been promoted to executive vice president, global services and chief ... Rice will retain his responsibilities as chief financial officer of ...
... , , , MELBOURNE, Australia, Dec. ... New Objective , Key points: , *Single injection of ... levels and sustained reduction in blood glucose levels , ... of pancreatic islets, and increase in insulin-producing beta cells ...
Cached Medicine Technology:Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas and Reduces Blood Glucose Levels in Diabetes 2Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas and Reduces Blood Glucose Levels in Diabetes 3
(Date:6/1/2015)... June 01, 2015 Note: Dr. Julian ... in breast cancer prevention. , A phase III trial ... postmenopausal women with ductal carcinoma in situ (DCIS) now ... prevention. , The study (NSABP B-35/NRG Oncology) looked at ... the standard five-year treatment with tamoxifen to those who ...
(Date:6/1/2015)... Northridge, CA (PRWEB) June 01, 2015 ... Ramin Assili are now offering patients a promotion on ... the price of Invisalign treatment is reduced to $3,700. ... treatment during the complimentary consultation and discuss the extent ... 2015, and it cannot be combined with any other ...
(Date:6/1/2015)... MD (PRWEB) June 01, 2015 InstantLabs ... identification test as part of a Cooperative Research and ... Administration (FDA). In accordance with U.S. Farm Bill ... legally marketed as catfish within the United States. ... in hours at the point-of need rather than requiring ...
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 If ... discomfort based on past experience, we have some encouraging ... from San Diego and one from San Marcos, Calif., ... a prototype for DuoOptimum Suction (DOS) Tip to provide ... other procedures. As such, it keeps a dental patient’s ...
(Date:6/1/2015)... Community Scene ( communityscene.com ), the ... of its free online platform designed to connect people ... and globally. , On Community Scene, members can share ... their community – including local news, activities for the ... can choose a home community or follow any community ...
Breaking Medicine News(10 mins):Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 4Health News:All-in-One Dental Aspirator Invented by InventHelp® Clients (SDB-733) 2Health News:Community Scene Launches the Largest Global Social Network for Communities 2
... usually go undetected during the early stages, according to ... initial symptoms of the condition, according to the // ... symptoms are the clubbed finger, swollen fingertips, and chest ... of the lungs or an analysis of the mucus ...
... and celecoxib (Celebrex) reduces breast cancer risk by 71%, ... of Medicine and Public Health's Randall Harris led the ... nonsteroidal anti-inflammatory drugs (NSAIDs) play a prominent role in ... researchers observed that while daily use of selective COX-2 ...
... turned out to be negative for the presence of ... by the health minister Datuk Dr Chua Soi Lek. ... however. ,The victim, Norhayati Awang is currently ... Raja Perempuan Zainab II. According to official reports, she ...
... had developed a new technology that will help in the ... a high risk. It is a blood test, which measures ... can detect typical; changes seen in the early liver cancer ... because live cancer is one of the most prevalent diseases. ...
... flu virus here comes another virus that us causing havoc. Known ... that manifests itself in the form of severe vomiting and diarrhea. ... the Norwalk virus. ,The virus has been known to affect ... as of now. What is concerning the authorities ...
... e-mail contribute towards strengthening and expanding social ties among the ... American Life Project. //It had earlier been said that social ... ,With the help of the Internet, people are ... though many of the people in those networks do not ...
Cached Medicine News:Health News:Early Detection Of Primary Liver Cancer Would Save Millions Of Lives 2
... The Magnes 2500 WH , with its ... full cortical coverage allowing the localization of ... millisecond temporal resolution and millimeter spatial resolution. ... secure patient database and rapid data processing ...
... and table configurations designed for a wide ... can capture 17 X 17 X-ray images ... flexible system includes a Bucky table, upright ... ceiling suspended multi-positioning unit. Versatile and economical, ...
The Oscor PACE 203 H is the third generation of Osypka line of External Dual Chamber Pacemakers. Based on over 20 years of pacing experience, the PACE 203 H represents todays standard in temporary du...
... Oscors proprietary quadripolar pacing ... consistent pacing and sensing in ... combining two bipolar wires in ... for the atrium and ventricle ...
Medicine Products: